Company Matinas BioPharma Holdings Inc Other OTC

Equities

US5768101058

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Bio Therapeutic Drugs

Inactive Instrument

End-of-day quote Other OTC Other stock markets
- ^USD	-

Mar. 27	Transcript : Matinas BioPharma Holdings, Inc., 2023 Earnings Call, Mar 27, 2024
Mar. 27	Matinas BioPharma Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology (LNC Platform). Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options. It is expanding the utilization of the LNC Platform with small molecules and small oligonucleotides outside of infectious disease, targeting inflammation and oncology. It is also investigating a variety of LNC formulations of two small oligonucleotides designed to target inflammatory cytokines IL-17A and TNFÎ±.

USD in Million	2022	Weight	2023	Weight	Delta
Novel Pharmaceutical Products 100.0 %	3	100.0 %	1	100.0 %	-65.62%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	3	100.0 %	1	100.0 %	-65.62%

Managers	Title	Age	Since
Jerome Jabbour FOU	Founder	50	13-04-30
Keith Kucinski DFI	Director of Finance/CFO	55	19-01-02
Hui Liu CTO	Chief Tech/Sci/R&D Officer	56	20-11-30
James Ferguson CTO	Chief Tech/Sci/R&D Officer	70	19-02-24
Theresa Matkovits PRN	Corporate Officer/Principal	56	18-10-14
Thomas Hoover PRN	Corporate Officer/Principal	55	21-12-05

Members of the board	Title	Age	Since
Herbert Conrad FOU	Founder	91	13-04-30
Natasha Giordano BRD	Director/Board Member	62	20-09-13
Eric Ende CHM	Chairman	55	17-04-02
James Scibetta BRD	Director/Board Member	59	13-10-31
Matthew Wikler BRD	Director/Board Member	74	17-12-31
Kathryn Corzo BRD	Director/Board Member	63	21-08-31
Jerome Jabbour FOU	Founder	50	13-04-30

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	250,816,164	244,482,252 ( 97.47 %)	0	97.47 %

Name	Equities	%	Valuation
Vanguard Global Advisers LLC 4.289 %	9,317,838	4.289 %	3 M $
Herbert Conrad 2.161 %	4,694,566	2.161 %	1 M $
Sargent Investment Group LLC 1.757 %	3,818,000	1.757 %	1 M $
BlackRock Institutional Trust Co. NA 1.151 %	2,501,011	1.151 %	677 774 $
Arkadios Wealth Advisors LLC 0.7475 %	1,624,000	0.7475 %	440 104 $
Geode Capital Management LLC 0.7256 %	1,576,513	0.7256 %	427 235 $
Neville, Rodie & Shaw, Inc. 0.5327 %	1,157,332	0.5327 %	313 637 $
JTC Employer Solutions Trustee Ltd. 0.3567 %	775,000	0.3567 %	210 025 $
STATE STREET CORPORATION 0.3279 %	712,471	0.3279 %	193 080 $
James Scibetta 0.2992 %	649,958	0.2992 %	176 139 $

Matinas BioPharma Holdings, Inc.

1545 Route 206 South Suite 302

07921-9999, Bedminster

+908 484 8805

http://www.matinasbiopharma.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs